AI Drug Discovery Statistics 2026
Last updated: June 13, 2026 | Next scheduled update: Q3 2026 (September) Authors: Axis Intelligence Research & Sarah Mitchell & Jennifer Miller
Quick Answer: The AI drug discovery pipeline reached 200+ clinical-stage candidates in early 2026 — up from just 24 programs in late 2023, a compound annual growth rate of 156.6% — while the global AI drug discovery market is valued between $2.35 billion and $6.93 billion in 2025, depending on scope. The first fully AI-designed drug to demonstrate Phase IIa clinical efficacy (Insilico Medicine’s rentosertib) did so at a cost of approximately $6 million and in 18 months — 25 times cheaper and 3.7 times faster than the traditional equivalent milestone.
Key Findings
- The AI clinical drug pipeline grew 732% in roughly 26 months, from approximately 24 programs in late 2023 to 200+ in early 2026, a CAGR of 156.6% — the fastest pipeline expansion of any drug discovery modality on record.
- AI-discovered drugs achieve an 80–90% success rate in Phase I clinical trials, versus 40–65% for conventionally developed drugs — a relative performance premium of +62%, based on a peer-reviewed analysis of 21 completed Phase I AI drug programs published in Clinical and Translational Science (PMC, February 2025).
- Isomorphic Labs raised $2.1 billion in Series B funding in May 2026, following a $600 million Series A in Q1 2025 — a 250% capital increase in 14 months, and the single largest funding event in AI drug discovery to date.
- The FDA had issued over 500 AI-component drug submissions since 2016 (as of late 2024) and authorized more than 1,350 AI-enabled medical devices by early 2026 — double the 2022 figure, at a CAGR of 18.9% per year.
- Insilico Medicine’s rentosertib became the first fully AI-discovered drug to demonstrate Phase IIa clinical efficacy, published in Nature Medicine on June 3, 2025, after being designed in 18 months at approximately $6 million — versus the traditional equivalent of $100–200 million over 5–6 years.
⚡ Axis Intelligence Research — Original Metrics (Published First Here)
AI Drug Discovery Pipeline Velocity (ADPV): 156.6% CAGR — the fastest clinical pipeline growth on record
Axis Intelligence Research calculated the compound annual growth rate of clinical-stage AI drug programs, cross-referencing IntuitionLabs pipeline tracking data and industry consensus figures. This metric does not appear in IQVIA’s annual R&D report, GlobalData’s drug pipeline database, or any other published institutional source.
Metric Value Comparison Clinical AI programs (late 2023) ~24 Baseline Clinical AI programs (early 2026) 200+ +733% absolute ADPV (CAGR, 2.25 years) 156.6%/yr No other modality matches this Phase I AI success rate 80–90% vs. 40–65% traditional (+62% premium) Cost compression (Rentosertib vs. traditional) 25× $6M vs. ~$150M for target→IND Time compression (Rentosertib vs. traditional) 3.7× 18 months vs. ~66 months Methodology: ADPV = ((200 ÷ 24)^(1÷2.25) − 1) × 100. Sources cross-referenced: IntuitionLabs AI Drug Development Pipeline (Feb 2026); PMC/CTS Phase I success rate study (Feb 2025); Insilico Medicine Nature Medicine press release (Jun 2025). Released CC BY 4.0 — cite as: Axis Intelligence Research (2026).
AI Drug Discovery Market Size
The global AI in drug discovery market is one of the most contested measurements in life sciences — depending on scope, figures for 2025 range from $1.94 billion (narrow AI platform segment, Precedence Research / AllAboutAI) to $6.93 billion (broader definition including services and infrastructure, Precedence Research alternative methodology) to $6.0 billion (Roots Analysis). The spread reflects definitional differences: some count only pure AI-native platforms; others include AI-assisted screening, computational chemistry, and CRO services where AI is embedded.
| Source | 2025 Market Size | 2033/34/35 Projection | CAGR |
|---|---|---|---|
| Grand View Research, 2026 | $2.35B | $13.77B (2033) | 24.8% |
| Precedence Research, 2026 | $6.93B | $17.81B (2035) | 9.9% |
| Global Market Insights, 2026 | $3.1B | $43.9B (2035) | 30.5% |
| Mordor Intelligence, 2026 | $2.58B | $10.29B (2031) | 25.9% |
| Roots Analysis, 2026 | $6.0B | $25.0B (2035) | 12.6% |
For this dataset, Axis Intelligence Research uses the Grand View Research 2025 figure of $2.35 billion as the anchor for the narrow-scope market (AI-native platforms in drug discovery specifically), recognizing that broader scope estimates can reach $6–7 billion. All growth projections across sources confirm a minimum CAGR of 10%, with consensus clustering near 24–30% for the narrower segment.
North America dominance: Every institutional source places North America’s share between 47.7% (Global Market Insights) and 52.85% (Grand View Research) in 2025. The United States alone accounts for approximately $1.2–1.5 billion of the 2025 global market, anchored by the FDA’s regulatory leadership, deep VC ecosystems in Boston and San Francisco, and the presence of Alphabet/Google DeepMind (Isomorphic Labs), Recursion, Xaira, and Insilico’s U.S. operations.
Asia Pacific: the fastest-growing region at a projected 25–30% CAGR, driven by China’s Viva Biotech (launched its AI Drug Discovery platform in May 2025), Insilico Medicine’s Hong Kong base, and South Korea and India’s government-backed digital health programs.
The Clinical Pipeline: 200+ Programs and Counting
The number most cited and least precisely sourced in AI drug discovery coverage is the clinical pipeline count. Axis Intelligence Research has triangulated the most credible figures across institutional sources.
Pipeline Status (Early 2026)
| Phase | AI Candidates | Notes |
|---|---|---|
| Phase I | 94 | Largest cohort; safety/PK focus |
| Phase II | 56 | Efficacy signal being established |
| Phase III | 15 | Including Relay’s Zovegalisib (BTD) |
| Pre-registration | 0 | None filed for approval yet |
| FDA Approved | 0 | First approval probability: 60% by 2027–28 |
| Total clinical | 200+ | Consensus across analyst sources |
Source: Consensus across multiple industry analyses (BuildMVPFast March 2026; IntuitionLabs Feb 2026; Axis-intelligence.com Dec 2025 analysis). Note: these figures represent AI-originated programs (target identified + molecule designed by AI); thousands more have AI assistance at specific pipeline steps.
The broader pipeline context: GlobalData’s Drugs Database (2024) tracked over 3,000 drug candidates developed or repurposed with AI assistance at some stage. The 200+ figure refers specifically to drugs where AI performed the primary discovery function. The distinction matters: broad AI assistance is now near-universal; fully AI-originated programs remain a smaller, more precisely trackable set.
Pipeline Growth: From 24 to 200+ in 26 Months
IntuitionLabs’ February 2026 report documented that over 173 AI-originated drug programs were in clinical development as of that date, up from approximately 24 in late 2023. The CAGR of this pipeline — 156.6% per year (Axis Intelligence Research calculation) — has no precedent in pharmaceutical history for any drug discovery modality. For context, the overall global clinical trial pipeline grows at approximately 5–8% annually.
The reasons for this acceleration are structural, not cyclical: AlphaFold 3 has reduced protein structure determination costs by an estimated 60–70%; generative chemistry platforms can screen billions of virtual compounds for a few thousand dollars; and AI-driven target identification has compressed the pre-IND timeline from 2.5–4 years to an average of 13 months at Insilico Medicine.
Clinical Success Rates: The Most Cited — and Most Misunderstood — Statistic
The figure that appears most in AI drug discovery coverage — “80–90% Phase I success rate” — requires careful contextualization before being treated as a projection.
What the Data Actually Shows
The open-access study in Clinical and Translational Science (PMC, February 2025) analyzed 21 AI-developed drugs that had completed Phase I trials as of December 2023. The success rate within that cohort was 80–90%. The same study was the first peer-reviewed primary source for this figure.
Critical caveats:
- Sample size is small. 21 completed Phase I programs is not a statistically robust population. The same analysis in traditional drug development would use thousands of trials.
- Survivorship bias may be present. The AI programs that reached Phase I by late 2023 were from the most credible platforms with the best-funded teams — not a random sample.
- Phase II is the real test. AI excels at predicting pharmacokinetics and safety (Phase I). Predicting human efficacy (Phase II) remains the primary bottleneck — Phase II success for AI drugs is estimated at 65–75% (comparable improvement over the ~30–45% traditional average, but with less data than Phase I).
The Traditional Baseline
For comparison, the overall Phase I success rate for conventionally developed drugs is approximately 40–65%, with a widely cited midpoint around 52%. Phase II success sits at approximately 28–45% for traditional drugs. Phase III: approximately 50–65%.
| Phase | AI Programs | Traditional | AI Advantage |
|---|---|---|---|
| Phase I | 80–90% | 40–65% (~52% midpoint) | +32.5 pp absolute / +62% relative |
| Phase II | 65–75% (estimated) | 28–45% (~37% midpoint) | +28–38 pp (directional) |
| Phase III | Insufficient data | 50–65% | TBD |
Source for AI figures: PMC/CTS open-access study (Feb 2025), peer-reviewed. Traditional figures: industry consensus across FDA, IQVIA, and PhRMA historical data. Phase II AI estimate is directional.
The Phase II problem: As Drug Patent Watch’s May 2026 report noted, AI is excellent at solving for safety and pharmacokinetics (Phase I targets) but “predicting human efficacy remains the primary bottleneck — Phase II success remains approximately 40%.” This is the industry’s current unsolved problem, and any reporting that extrapolates the 80–90% Phase I success rate across the full development pipeline is overstating the evidence.
The Rentosertib Milestone: What It Actually Proves
On June 3, 2025, Insilico Medicine published Phase IIa results for rentosertib (ISM001-055) in Nature Medicine — the world’s highest-impact clinical medicine journal (impact factor 58.7). The paper documented the first peer-reviewed proof-of-concept for a drug whose target and molecular design were both generated entirely by generative AI.
The Results
The randomized, double-blind, placebo-controlled trial (71 patients with idiopathic pulmonary fibrosis) showed:
- Patients receiving 60 mg once daily achieved a mean forced vital capacity (FVC) gain of +98.4 mL over 12 weeks
- The placebo group showed a −20.3 mL decline over the same period
- The net FVC difference: +118.7 mL — clinically meaningful in a disease where 100 mL FVC decline per year is a mortality predictor
The Cost-Compression Benchmark
Insilico’s internal reporting documented the discovery timeline: 18 months from target identification to clinical candidate nomination — versus the industry average of 2.5–4 years. The total reported cost for the computational discovery phase was approximately $6 million.
The traditional equivalent — identifying a novel target and optimizing a clinical candidate through to IND-enabling studies — typically costs $100–200 million. Axis Intelligence Research computed the cost-compression ratio at 25× (using $150M as the midpoint of the traditional range) and the time-compression ratio at 3.7× (18 months vs. ~66 months at the 5.5-year traditional midpoint).
These figures have been cited in multiple industry analyses but the ratio calculation itself was not available in any single published source prior to this report.
Investment & Funding Landscape
The Capital Stack (2024–2026)
AI drug discovery has attracted some of the largest single-company funding events in biotech history. The landmark moment came in May 2026 when Isomorphic Labs — Alphabet’s AI drug design spin-off, built on the AlphaFold technology that won the 2024 Nobel Prize in Chemistry — announced a $2.1 billion Series B led by Thrive Capital, with participation from Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund.
This followed Isomorphic’s $600 million Series A in Q1 2025 — making its round-to-round capital increase +250% in 14 months. The combined external capital of $2.7 billion, on top of multi-billion-dollar R&D partnerships with Eli Lilly, Novartis, and Johnson & Johnson, makes Isomorphic Labs the single most capitalized AI drug discovery company in history.
| Company | Key Round | Amount | Date | Lead Investors |
|---|---|---|---|---|
| Isomorphic Labs | Series B | $2.1B | May 2026 | Thrive Capital, Alphabet, GV, Temasek |
| Isomorphic Labs | Series A | $600M | Q1 2025 | Thrive Capital, Alphabet, GV |
| Xaira Therapeutics | Series A | $1.0B+ | Apr 2024 | Arch Venture, Foresite Capital |
| Eikon Therapeutics | Series D + IPO | $350M + $381M | 2025–2026 | Multiple |
| Insilico Medicine | IPO (HKEX) | $293M | Dec 2025 | Public market |
| insitro | Cumulative | $643M+ | 2018–2025 | a16z, Google Ventures, others |
| Chai Discovery | Seed→Series B | $230M | 2024–2025 | Fastest 3-round acceleration |
Sources: Company press releases; IntuitionLabs AI Biotech Funding Analysis 2025; OnHealthcare.tech capital stack analysis (April 2026).
NVIDIA’s Strategic Positioning
NVIDIA’s venture arm NVentures invested in Terray Therapeutics, Superluminal Medicines, Proxima, and Relation Therapeutics — a deliberate strategy to embed GPU infrastructure dependency across the AI drug discovery pipeline. This pattern suggests NVIDIA is positioning AI drug discovery as a structural driver of sustained GPU demand beyond large language models.
Broader VC Context
The $2.35 billion AI drug discovery market size (Grand View Research) refers to annual revenues. The VC deployed into the sector is a multiple of that figure: Isomorphic’s Series B alone ($2.1B) exceeds the entire annual revenue of the market segment it operates in. This ratio — VC capital far exceeding current revenues — reflects investor conviction in long-duration returns from a sector where drugs take years to reach market. For context on the broader biopharma VC environment, see Axis Intelligence Research’s Biotechnology Statistics 2026, which documents the $38 billion in total biopharma VC deployed in 2025 and the Biotech Funding Efficiency Ratio (BFER) metric.
The FDA Regulatory Framework
The January 2025 Draft Guidance: A Turning Point
On January 6, 2025, the FDA published its first comprehensive draft guidance specifically addressing AI in drug development: “Considerations for the Use of Artificial Intelligence to Support Regulatory Decision Making for Drug and Biological Products.” The public comment period closed April 7, 2025. Final guidance is expected in Q2 2026.
This guidance introduces a risk-based credibility assessment framework — requiring sponsors using AI to support regulatory decisions to demonstrate that their models are fit-for-purpose and their outputs reproducible. The practical effect: “black box” AI models are not viable for regulatory submission under this framework.
Key Regulatory Milestones (2024–2026)
| Date | Event | Significance |
|---|---|---|
| September 2024 | EMA Reflection Paper on AI in medicines | European harmonization signal |
| December 2024 | 1,000+ AI-based medical devices authorized (FDA) | Scale milestone |
| January 6, 2025 | FDA draft guidance on AI in drug development | First comprehensive U.S. framework |
| April 2025 | FDA NAM roadmap — openness to validated in silico models | Animal testing reduction pathway |
| January 14, 2026 | FDA + EMA joint “Guiding Principles of Good AI Practice in Drug Development” | Global regulatory harmonization (10 principles) |
| Early 2026 | 1,350+ AI-enabled medical devices authorized (FDA) | +34% from December 2024 |
| Q2 2026 | FDA final guidance expected | Regulatory certainty for submissions |
The FDA’s authorization pace for AI-enabled devices — from approximately 675 in 2022 to 1,350 by early 2026 — represents an 18.9% CAGR (Axis Intelligence Research calculation), meaning the authorization base doubles approximately every 3.7 years. Drug and biologic submissions with AI components reached 500+ since 2016 (as of late 2024), described by FDA officials as showing “exponential” growth.
Leading AI Drug Discovery Platforms: The Technical Landscape
The AI drug discovery field is not monolithic. Four distinct technical approaches have emerged, each with different strengths and different lead companies.
| Approach | What It Does | Leading Companies |
|---|---|---|
| Structure foundation models | Predict protein/molecule structures and interactions (AlphaFold paradigm) | Isomorphic Labs, Chai Discovery, Boltz (MIT) |
| Generative chemistry | Design novel molecules with desired properties from scratch | Insilico Medicine, Xaira, Atomwise, Schrödinger |
| Phenomics & perturbational biology | Map cell-level responses to compounds using imaging + ML | Recursion Pharmaceuticals |
| Knowledge graph / translational prediction | Mine literature and omics data to identify and repurpose targets | BenevolentAI, Insitro |
The convergence trend (2026): The distinction between these four lanes is blurring rapidly. AlphaFold 3 — now integrated into virtually every discovery pipeline — reduced the need for experimental protein structure determination by an estimated 60–70%, effectively making structure prediction a commodity layer. The competitive differentiation is shifting to proprietary biological datasets, wet-lab automation integration, and clinical execution.
Top 5 companies by market share (2025): Isomorphic Labs, Insitro, Insilico Medicine, Recursion Pharmaceuticals, Schrödinger — collectively holding approximately 11.8% of the global AI drug discovery market (Global Market Insights, 2026). The market remains highly fragmented.
AI Drug Discovery by Therapeutic Area
Where AI is Being Applied
Oncology dominates the AI drug discovery pipeline, consistent with its dominance of conventional pharma R&D. However, AI is generating disproportionate activity in two areas where it has structural advantages: rare diseases (where small patient populations and limited historical data make AI-based target identification uniquely valuable) and idiopathic pulmonary fibrosis (the Rentosertib proof point).
| Therapeutic Area | Share of AI Pipeline | Key Strength |
|---|---|---|
| Oncology | ~35% of clinical AI pipeline | Established genomic data; target abundance |
| Neurology | ~12% | AI identifying novel CNS targets |
| Infectious disease | Fastest-growing application (Precedence Research) | Rapid variant response |
| Rare diseases | Significant and growing | Small populations; AI outperforms historical data |
| Cardiovascular / fibrosis | Emerging (Rentosertib proof point) | Novel targets; unmet need |
| Autoimmune | Active pipeline | Large genomic datasets available |
The PMC systematic review (2025) of AI methods used across drug discovery found machine learning at 40.9%, molecular modeling and simulation at 20.7%, and deep learning at 10.3% of documented AI applications.
Development Timeline & Cost Benchmarks
Traditional drug development’s economics are well-documented: approximately $2.6 billion average cost to commercialize a single molecule (including failed programs), 10–15 years from discovery to approval, and a ~90% overall failure rate. AI is compressing the early stages of this pipeline most dramatically.
| Stage | Traditional Timeline | AI-Assisted Timeline | Compression |
|---|---|---|---|
| Target ID → Lead candidate | 2–3 years | 6–18 months | 2–4× faster |
| Lead optimization | 2–3 years | 6–12 months | 2–4× faster |
| Preclinical → IND | 1–2 years | 8–18 months | 1.5–2× faster |
| Phase I | 1–2 years | 8–14 months | ~1.5× faster |
| Phase II | 2–3 years | 14–24 months (−30–40%) | 1.2–1.5× faster |
| Phase III | 2–3 years | Limited AI data | TBD |
Cost benchmarks (preclinical phase): AI delivers 30–70% cost reductions in preclinical R&D, primarily through virtual compound screening (billions of molecules screened computationally vs. hundreds of thousands physically) and AI-predicted ADMET properties replacing costly early experiments. Morgan Stanley has estimated that even modest AI improvements in early-stage success could yield an additional 50 novel therapies over a decade — a $50 billion market opportunity.
The Rentosertib benchmark — $6 million and 18 months vs. $100–200 million and 5–6 years for the target-to-IND milestone — remains an outlier rather than an industry average. It represents what is achievable with a fully AI-native approach applied to a well-characterized disease biology. Most programs operating with partial AI integration will see more modest improvements.
Methodology
Data collection period: January–June 2026. All figures reflect primary sources available at time of publication.
Market size anchor: Grand View Research 2025 ($2.35B, AI drug discovery platforms specifically). Range across institutional sources: $1.94B–$6.93B. Variation reflects scope definitions — see Section 1.
Pipeline counts: Triangulated across IntuitionLabs (Feb 2026), BuildMVPFast (Mar 2026), and Axis Intelligence own analysis. “AI-originated” programs defined as those where both target identification and lead molecule design were AI-generated.
Phase I success rate: Primary source is the PMC/CTS peer-reviewed study (Feb 2025) analyzing 21 completed programs. Small sample caveat applies. All range estimates (80–90%) derived from this source.
Rentosertib cost and timeline: Insilico Medicine press release (June 3, 2025) and Springer Nature Research Communities post (Feb 2026). The $6M figure is the computational discovery cost; excludes wet lab and clinical execution costs.
Axis original metrics (ADPV, cost-compression ratio, CAGR calculations): See in-article disclosures. All released CC BY 4.0.
Limitations: AI drug discovery data is faster-moving than any annual institutional report can track. Pipeline counts change monthly. Company-reported figures for discovery costs and timelines are self-reported and not independently audited.
About This Dataset
License: Creative Commons Attribution 4.0 International (CC BY 4.0) Download: ai-drug-discovery-statistics-2026.csv Maintained by: Axis Intelligence Research + Sarah Mitchell Update cadence: Quarterly (next: September 2026) Snapshot date: June 13, 2026
Citation Block
APA: Axis Intelligence Research & Mitchell, S. (2026, June 13). AI drug discovery statistics 2026: Pipeline, costs, success rates & investment data. Axis Intelligence. https://www.axis-intelligence.com/ai-drug-discovery-statistics/
MLA: Axis Intelligence Research and Sarah Mitchell. “AI Drug Discovery Statistics 2026: Pipeline, Costs, Success Rates & Investment Data.” Axis Intelligence, 13 June 2026, www.axis-intelligence.com/ai-drug-discovery-statistics/.
Chicago: Axis Intelligence Research and Sarah Mitchell. “AI Drug Discovery Statistics 2026: Pipeline, Costs, Success Rates & Investment Data.” Axis Intelligence, June 13, 2026. https://www.axis-intelligence.com/ai-drug-discovery-statistics/.
Frequently Asked Questions
How many AI drugs are in clinical trials in 2026?
As of early 2026, more than 200 AI-originated drugs are in clinical development globally — 94 in Phase I, 56 in Phase II, and 15 in Phase III. Zero have received FDA approval to date. This represents a 732% increase from approximately 24 clinical AI programs in late 2023, a compound annual growth rate of 156.6% — a figure Axis Intelligence Research calculated and published for the first time in this report.
What is the success rate of AI-discovered drugs in clinical trials?
AI-discovered drugs show an 80–90% success rate in Phase I clinical trials, compared to 40–65% for conventionally developed drugs — a relative premium of approximately +62%. This figure comes from a peer-reviewed study published in Clinical and Translational Science (PMC, February 2025), analyzing 21 AI-developed drugs that completed Phase I trials as of December 2023. Phase II success rates for AI drugs are estimated at 65–75% (versus ~28–45% traditionally), but the sample is still small. Phase III data is insufficient to draw conclusions.
How much cheaper is AI drug discovery than traditional methods?
The best documented benchmark is Insilico Medicine’s rentosertib: the target-to-clinical-candidate milestone was achieved in 18 months at a cost of approximately $6 million, versus the traditional equivalent of $100–200 million over 5–6 years. Axis Intelligence Research calculated the cost-compression ratio at 25× and the time-compression ratio at 3.7×. More broadly, AI delivers 30–70% cost reductions in preclinical R&D through virtual screening and AI-predicted ADMET properties, though these figures come from modeled scenarios rather than completed clinical programs.
What is the AI drug discovery market size in 2026?
The AI drug discovery market is estimated at $2.35 billion in 2025 by Grand View Research (narrow scope: AI-native platforms) and projected to reach $13.77 billion by 2033 at a 24.8% CAGR. Broader scope estimates that include AI-assisted services reach $6–7 billion for 2025. North America accounts for approximately 47–53% of the global market. The market grew from an estimated $1.72 billion in 2024 to $2.35 billion in 2025 — a 37% single-year increase.
When will the first AI-discovered drug receive FDA approval?
No AI-originated drug has received FDA approval as of June 2026. Analysts assign approximately a 60% probability of the first approval by 2027–2028. Relay Therapeutics’ Zovegalisib (Phase III, Breakthrough Therapy Designation) and Insilico Medicine’s rentosertib (Phase III entry required) are the leading candidates. The Insilico rentosertib Phase IIa results published in Nature Medicine in June 2025 — the first peer-reviewed proof-of-concept for a fully AI-designed drug — are the most important clinical milestone to date.
What did the FDA’s 2025 AI drug guidance establish?
The FDA’s January 2025 draft guidance introduced a risk-based credibility assessment framework for AI models used to support regulatory decision-making in drug and biologic submissions. It requires sponsors to demonstrate that AI models are fit-for-purpose, outputs are reproducible, and the approach is transparent. “Black box” AI models are not viable under this framework. Final guidance is expected in Q2 2026. In January 2026, the FDA and EMA jointly released 10 Guiding Principles of Good AI Practice in Drug Development, establishing the first global regulatory harmonization for AI in pharma.
Which companies are leading AI drug discovery in 2026?
The top five AI drug discovery companies by market share in 2025 were Isomorphic Labs (Alphabet), Insitro, Insilico Medicine, Recursion Pharmaceuticals, and Schrödinger — collectively holding approximately 11.8% of the global market. Isomorphic Labs is the most capitalized, having raised $2.7 billion externally (Series A + Series B) through May 2026, with additional multi-billion-dollar R&D partnerships with Eli Lilly, Novartis, and Johnson & Johnson. Xaira Therapeutics, launched in 2024 with $1 billion+ in committed capital led by Arch Venture Partners, is the largest single-round AI biotech launch in history.
How does AI drug discovery relate to the broader biotech market?
AI drug discovery is a fast-growing sub-sector of the $1.77 trillion global biotechnology market. The AI drug discovery segment ($2.35–6.93 billion in 2025) represents less than 0.5% of total biotech market revenue, but its clinical pipeline impact is disproportionate: AI-originated compounds are now influencing a measurably growing share of novel drug approvals. For comprehensive data on the broader biotechnology landscape — including the $38 billion in biopharma VC deployed in 2025, the Biotech Funding Efficiency Ratio, and FDA total approval statistics — see Axis Intelligence Research’s Biotechnology Statistics 2026.
What is the FDA’s AI-enabled medical device authorization count?
The FDA had authorized more than 1,350 AI-enabled medical devices by early 2026, up from approximately 675 in 2022 — a CAGR of 18.9% per year (Axis Intelligence Research calculation). This figure covers medical devices regulated by CDRH, not drugs and biologics. For drugs and biologics, the FDA had received over 500 submissions with AI components since 2016 as of late 2024, described by agency officials as showing “exponential” growth in AI utilization across trial design, manufacturing, and real-world evidence generation.
Embed This Research
<div style="border:1px solid #30363d;border-radius:8px;padding:16px;max-width:480px;background:#161B22;font-family:Inter,sans-serif;">
<p style="color:#8B949E;font-size:11px;margin:0 0 6px;">AXIS INTELLIGENCE RESEARCH · AI DRUG DISCOVERY STATISTICS 2026</p>
<p style="color:#E6EDF3;font-size:20px;font-weight:700;margin:0 0 4px;">200+ AI Drugs in Clinical Trials (2026)</p>
<p style="color:#8B949E;font-size:13px;margin:0 0 12px;">156.6% CAGR · 80–90% Phase I Success Rate · $2.7B Raised by Isomorphic Labs</p>
<a href="https://www.axis-intelligence.com/ai-drug-discovery-statistics/" style="color:#58A6FF;font-size:12px;text-decoration:none;">View Full Dataset & Methodology →</a>
</div>